Renata PLC (DSE:RENATA)

Bangladesh flag Bangladesh · Delayed Price · Currency is BDT
395.40
-3.00 (-0.75%)
At close: Dec 4, 2025
-38.59%
Market Cap 45.35B
Revenue (ttm) 44.03B
Net Income (ttm) 2.37B
Shares Out 114.70M
EPS (ttm) 20.64
PE Ratio 19.15
Forward PE 12.73
Dividend 5.50 (1.39%)
Ex-Dividend Date Nov 18, 2025
Volume 11,928
Average Volume 26,323
Open 402.00
Previous Close 398.40
Day's Range 394.00 - 402.00
52-Week Range 372.00 - 668.00
Beta -0.09
RSI 38.15
Earnings Date Jan 25, 2026

About Renata

Renata PLC manufactures, markets, and distributes pharmaceuticals, animal health medicines, oncology-based, agro-based, poultry, and consumer products in Bangladesh. The company offers generic products, including amantadine, clindamycin, clindamycin, colchicine, dipyridamole, escitalopram, fludrocortisone acetate, hydrocortisone, prednisolone, propylthiouracil, sertraline hydrochloride, terbinafine, and topiramate tablet and capsules. It also offers specialty products, such as SHK-024, an antidepressant, and SHK 007, to reduce toxicity in pedia... [Read more]

Industry Pharmaceutical Preparations
Founded 1972
Employees 8,366
Stock Exchange Dhaka Stock Exchange
Ticker Symbol RENATA
Full Company Profile

Financial Performance

In 2025, Renata's revenue was 42.89 billion, an increase of 13.74% compared to the previous year's 37.71 billion. Earnings were 2.22 billion, a decrease of -38.58%.

Financial Statements

News

There is no news available yet.